Artal Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Artal Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-121,756	Closed	-$13.1M	–	138
2023 Q1	$13.1M	Buy	+121,756	New	+$14M	0.78%	31

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Artal Group's RXDX Position: Q2 2023 in Review

Artal Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 121,756 shares — an estimated $13.1M sold.

Artal Group first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $13.1M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Artal Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Artal Group sold 121,756 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $13.1M.
Artal Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Artal Group's Prometheus Biosciences, Inc. Common Stock position peaked at $13.1M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.